News

Oblique Therapeutics has entered into

Oblique Therapeutics has entered into a discovery agreement with a global leader in diabetes medicines and care regarding the development of two functional antibodies against type 2 diabetes targets.

Oblique Therapeutics has in-licensed

Oblique Therapeutics has in-licensed three chemical series of novel undisclosed anticancer agents from the US National Institute of Health and the Karolinska Institute in Stockholm, Sweden.